Immunic Future Growth

Future criteria checks 0/6

Immunic is forecast to grow earnings and revenue by 6.4% and 93.6% per annum respectively while EPS is expected to grow by 16.9% per annum.

Key information

6.4%

Earnings growth rate

16.9%

EPS growth rate

Biotechs earnings growth	24.4%
Revenue growth rate	93.6%
Future return on equity	n/a
Analyst coverage	Low
Last updated	08 May 2024

Recent future growth updates

Recent updates

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Jan 22

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Oct 13

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

Jun 27

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Oct 20

Earnings and Revenue Growth Forecasts

NasdaqGS:IMUX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-117	N/A	N/A	3
12/31/2025	N/A	-100	N/A	N/A	4
12/31/2024	N/A	-93	N/A	N/A	5
3/31/2024	N/A	-98	-76	-75	N/A
12/31/2023	N/A	-94	-71	-71	N/A
9/30/2023	N/A	-129	-72	-72	N/A
6/30/2023	N/A	-127	-68	-68	N/A
3/31/2023	N/A	-125	-64	-64	N/A
12/31/2022	N/A	-120	-65	-65	N/A
9/30/2022	N/A	-85	-74	-74	N/A
6/30/2022	N/A	-83	-78	-78	N/A
3/31/2022	N/A	-79	-91	-91	N/A
12/31/2021	N/A	-93	-83	-83	N/A
9/30/2021	N/A	-83	-74	-74	N/A
6/30/2021	N/A	-77	-68	-68	N/A
3/31/2021	N/A	-70	-48	-48	N/A
12/31/2020	N/A	-44	-46	-46	N/A
9/30/2020	N/A	-41	-39	-38	N/A
6/30/2020	N/A	-36	-33	-32	N/A
3/31/2020	N/A	-39	-34	-34	N/A
12/31/2019	N/A	-35	-29	-29	N/A
9/30/2019	N/A	-32	-26	-26	N/A
6/30/2019	N/A	-26	-22	-22	N/A
3/31/2019	N/A	-14	-13	-13	N/A
12/31/2018	N/A	-12	-10	-10	N/A
9/30/2018	N/A	-10	-10	-10	N/A
12/31/2017	N/A	-10	N/A	-10	N/A
12/31/2016	0	-1	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMUX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMUX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMUX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMUX is forecast to have no revenue next year.

High Growth Revenue: IMUX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IMUX's Return on Equity is forecast to be high in 3 years time

Immunic Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

No longer forecast to breakeven

Price target decreased by 32% to US$9.00

Forecast to breakeven in 2026

Price target decreased by 15% to US$18.00

Price target decreased to US$21.17

Price target decreased to US$21.17

Recent updates

New minor risk - Profitability

No longer forecast to breakeven

Immunic, Inc. to Report Q1, 2024 Results on May 08, 2024

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Immunic, Inc., Annual General Meeting, Jun 11, 2024

Price target decreased by 32% to US$9.00

Immunic, Inc. to Report Fiscal Year 2023 Results on Feb 22, 2024

New major risk - Shareholder dilution

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Immunic, Inc. announced that it expects to receive $240 million in funding from BVF Partners L.P., Avidity Partners, LLC, Janus Henderson Investors, Soleus Capital, RTW Investments, LP, Adage Capital Management, L.P.

Forecast to breakeven in 2026

New major risk - Financial position

Immunic, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis Vidofludimus and Its Salts

Immunic, Inc. Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Immunic Reports Positive Interim Data from Phase 2 Calliper Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Immunic, Inc. Completes Enrollment of Its Phase 2 CallIPER Trial ofidofludimus Calcium in Progressive Multiple Sclerosis

New major risk - Share price stability

Immunic, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

Immunic, Inc. to Report Q1, 2023 Results on May 11, 2023

Immunic, Inc. Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

High number of new directors

Price target decreased by 15% to US$18.00

Immunic, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Independent Director recently bought US$103k worth of stock

Immunic, Inc Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

High number of new directors

Price target decreased to US$21.17

Price target decreased to US$21.17

Immunic, Inc. Provides Impairment Guidance for the Quarter Ending December 31, 2022

Immunic, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Price target increased to US$28.75

Immunic, Inc. Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Immunic, Inc. announced that it expects to receive $59.949037 million in funding from a group of investors

Immunic stock gains on $60M oversubscribed PIPE financing

Immunic, Inc Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects

Immunic, Inc. Receives Notice of Allowance for Composition-Of-Matter Patent in the United States for IMU-856, A Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium

Price target decreased to US$22.40

Immunic GAAP EPS of -$0.72 in-line

Immunic, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Immunic, Inc. Announces Executive Changes

Immunic, Inc.(NasdaqGS:IMUX) dropped from Russell 2000 Dynamic Index

Immunic, Inc. Announces Publication of Data From its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology

Immunic, Inc. Reports Top-Line Data from Phase 2 Caldose-1 Trial of Vidofludimus Calcium in Patients with Moderate-To-Severe Ulcerative Colitis

Price target decreased to US$49.43

Executive Chairman recently bought US$50k worth of stock

Immunic, Inc. Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

Immunic, Inc. to Report Q1, 2022 Results on May 10, 2022

High number of new directors

Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis

Immunic, Inc. to Report Fiscal Year 2021 Results on Feb 24, 2022

Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of Its Phase I Clinical Trial of IMU-935

Immunic, Inc. Announces Enrollment of the First Patient in Its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer

Here's Why We're Watching Immunic's (NASDAQ:IMUX) Cash Burn Situation

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

Immunic, Inc.(NasdaqGS:IMUX) dropped from Russell 2500 Growth Index

Executive Chairman recently bought US$51k worth of stock

We're Hopeful That Immunic (NASDAQ:IMUX) Will Use Its Cash Wisely

Immunic EPS misses by $0.95

New 90-day low: US$14.80

Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

New 90-day high: US$20.50